Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Korosho to Send Missions to the US, UK and France
February 18, 2008
- SELF-MEDICATION NEWS IN BRIEF
February 18, 2008
- Mediceo Paltac to Embark on Generics Business in Earnest
February 11, 2008
- BUSINESS NEWS IN BRIEF
February 11, 2008
- Shigeo Oyagi Elected President, CEO of Teijin Limited
February 11, 2008
- All ARBs, SSRIs to Be Re-priced
February 11, 2008
- Repeat Consultation Fee for Clinics Will Not Be Cut: Chuikyo
February 11, 2008
- Actemra to Be Approved for RA
February 11, 2008
- REGULATORY NEWS IN BRIEF
February 11, 2008
- Japan Should Take Part in More Multinational Clinical Trials: JMACCT Conference
February 11, 2008
- Live Vaccine Development Important for New-type Influenza
February 11, 2008
- R&D NEWS IN BRIEF
February 11, 2008
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
February 11, 2008
- TOPICS／Merck Seiyaku Renamed Mylan Seiyaku
February 11, 2008
- Chugai's Sunrise 2012 Plan Calls For Sales of \460 Bil.
February 11, 2008
- Takeda Acquires Amgen in Japan
February 11, 2008
- NEW PRODUCTS／Bayer Launches EOB Primovist for MRI of the Liver
February 11, 2008
- So-net M3 Launches DB of Doctors Interested in Participating in Clinical Trials
February 4, 2008
- Mochida to Embark on Generic Business in Earnest
February 4, 2008
- Attractive Drug Market Must Be Created in Japan: Industry Leaders
February 4, 2008
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…